FDA Approves First Medication for Liver Inflammation NASH
The US FDA has approved the first medication for nonalcoholic steatohepatitis (NASH), a liver inflammation condition affecting millions. The medication, Rezdiffra, developed by Madrigal Pharmaceuticals, offers a groundbreaking solution for moderate to advanced fibrosis resulting from NASH. Clinical trials showed promising outcomes, with over 25% of participants achieving NASH resolution without fibrosis worsening. However, the medication may have significant interactions with certain other drugs, and a post-approval study is needed to verify its clinical benefits.